Citrate Anticoagulation for Postdilution Hemofiltration

Last updated: May 7, 2020
Sponsor: Heinrich-Heine University, Duesseldorf
Overall Status: Active - Recruiting

Phase

N/A

Condition

Renal Failure

Kidney Disease

Kidney Failure

Treatment

N/A

Clinical Study ID

NCT03969966
2018-82
  • Ages > 18
  • All Genders

Study Summary

This study evaluates a protocol for regional citrate anticoagulation in critically ill patients with acute kidney injury who are treated with continuous veno-venous haemofiltration in postdilution mode.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • acute kidney injury

  • critical illness and treatment at ICU

Exclusion

Exclusion Criteria:

  • age < 18 years

  • pregnancy or breast feeding

  • severe lactate acidosis ( > 10 mmol/l) for longer than 6 hours and pH < 7.2

Study Design

Total Participants: 100
Study Start date:
January 14, 2019
Estimated Completion Date:
July 31, 2021

Study Description

Acute kidney injury (AKI) requiring continuous renal replacement therapy (CCRT occurs in approx. 15 % of all intensive care patients. A sustained and prolonged filter running time is required to deliver an effective dialysis dose. This requires effective anticoagulation. Today, regional citrate anticoagulation (RCA) is preferred over systemic anticoagulation because of prolonged filter lifetimes and less adverse effects.

We here study prospectively patients with AKI who are treated with continuous veno-venous haemofiltration using an RCA protocol.

We will evaluate all parameters of CRRT including filter running times, delivered dialysis dose, causes for treatment interruption and control of pH and electrolytes.

Connect with a study center

  • Intensivstation ZOM1 Klinik für Anästhesiologie Universitätsklinikum Düsseldorf

    Duesseldorf, 40225
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.